NCT06202261 - A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

October 31, 2027

Conditions

Metastatic Breast CancerRecurrent Breast CancerAdvanced Malignancies

Interventions

DRUG

TQB2930 for injection

TQB2930 for injection is a HER2 bispecific antibody.

DRUG

Paclitaxel for injection (albumin-bound)

It is an anti-microtubule chemotherapy drug

DRUG

TQB3616 capsule

TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.

DRUG

Fulvestrant injection

Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol

DRUG

Capecitabine tablets

Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.

DRUG

Vinorelbine tartrate injection

Vinorelbine is an anti-tumor drug of vinca alkaloids.

DRUG

Eribulin mesylate injection

Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.

DRUG

gemcitabine hydrochloride for injection

Gemcitabine is a cell cycle specific anti-metabolic anticancer agent

Trial Locations (2)

150001

RECRUITING

Affiliated cancer hospital of harbin medical university, Harbin

400000

RECRUITING

Affiliated Cancer Hospital of Chongqing University, Chongqing